| Kelly Victoria Joelle Loehr, LCPC | |
|
1075 E Park Blvd, Boise, ID 83712-7722 | |
| (208) 381-5970 | |
| Not Available |
| Full Name | Kelly Victoria Joelle Loehr |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 1075 E Park Blvd, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043724065 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | LPC-6713 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelly Victoria Joelle Loehr, LCPC 190 E Bannock St, Boise, ID 83712-6241 Ph: () - | Kelly Victoria Joelle Loehr, LCPC 1075 E Park Blvd, Boise, ID 83712-7722 Ph: (208) 381-5970 |
News Archive
Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).
Mutations in FHL1 are present in several myopathies, including reducing-body myopathy (RBM), but until now, both the molecular mechanisms causing the disease, and the regular function of FHL1 in healthy tissue, remained unknown.
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
Responding to federal pressure, state officials said they would slash the number of waiting applicants nearly in half over the next six weeks. Kansas, meanwhile, promised to fix its computers so they can communicate with the federal system.
InspireMD, developer of the novel MGuard(TM), a combination of a coronary stent merged with an embolic protection specifically designed for Acute MI (AMI) patients, received significant exposure at the ICI, Innovations in Interventional Cardiology, meeting this week in Tel-Aviv. InspireMD presented long-term data, including two years of clinical follow-up, to support the Company's MGuard stent technology.
› Verified 9 days ago
Roxanne L Pickerel, M.S., LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 203 W Fort St, Boise, ID 83702 Phone: 208-841-8109 Fax: 208-203-1879 | |
Mrs. Mary Claire Fery, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 410 S Orchard St Ste 128, Boise, ID 83705 Phone: 208-918-1283 | |
Rachel Marie Piazza Voight, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1075 E Park Blvd, Boise, ID 83712 Phone: 208-381-5970 | |
Ms. Terri Turpin, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1408 W Hays St, Boise, ID 83702 Phone: 208-429-5730 Fax: 208-336-7125 | |
Mr. Charles Edward Vollet, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1510 Robert Street, Suite 101, Boise, ID 83705 Phone: 208-344-0844 Fax: 208-344-0592 | |
Debra Lynne Gallagher, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1111 S Orchard St Ste 290, Boise, ID 83705 Phone: 208-343-2770 | |
Caitlin Goicoechea, Counselor Medicare: Not Enrolled in Medicare Practice Location: 8950 W Emerald St Ste 178, Boise, ID 83704 Phone: 208-376-7083 |